Effect of experimental hyperhomocysteinemia on plasma lipid profile, insulin sensitivity and paraoxonase 1 in the rat

Hyperhomocysteinemia (hHcy) is a well-known risk factor of cardiovascular diseases, however, the mechanism of its detrimental effect is incompletely understood. Some studies suggest that, paradoxically, hHcy may promote traditional risk factors such as hyperlipidemia. We examined the effect of experimental hHcy on plasma lipid profile, glucose and insulin concentrations as well as on high-density lipoprotein (HDL)-associated antiatherosclerotic enzyme, paraoxonase 1 (PON1). Hyperhomocysteinemia was induced by feeding male Wistar rats with diet enriched with methionine or diet enriched in methionine and deficient in folate, vitamin B6 and B12 for 8 weeks. These diets resulted in the 3.3- and 9.6-fold elevation of plasma Hcy, respectively. Plasma total and HDL-cholesterol, triglycerides and apolipoprotein A-I were similar in all groups. High-methionine diets had no effect on fasting plasma glucose but significantly increased fasting plasma insulin concentration indicating impaired ability of insulin to suppress hepatic glucose output. PON1 activity was unchanged in high methionine vitamin B-sufficient diet-fed rats, but was decreased by 30-40% toward various substrates in high methionine vitamin B-deficient diet-fed animals. The results indicate that hHcy has no effect on lipid metabolism, however, induces insulin resistance and, above certain Hcy level, PON1 deficiency. Impaired insulin signaling and reduced PON1 activity may contribute to detrimental effects of hHcy. Adipobiology 2012; 4: 77-84.

[1]  Hua Jiang,et al.  Altered expression of apoA-I, apoA-IV and PON-1 activity in CBS deficient homocystinuria in the presence and absence of treatment: possible implications for cardiovascular outcomes. , 2012, Molecular genetics and metabolism.

[2]  H. Jakubowski,et al.  Paraoxonase 1 and homocysteine metabolism , 2012, Amino Acids.

[3]  P. Atanassova,et al.  Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites. , 2011, Atherosclerosis.

[4]  S. Tyagi,et al.  Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. , 2011, Antioxidants & redox signaling.

[5]  Y. Zhang,et al.  Relationship between lipid profiles and plasma total homocysteine, cysteine and the risk of coronary artery disease in coronary angiographic subjects , 2011, Lipids in Health and Disease.

[6]  G. Ferretti,et al.  Effect of homocysteinylation on high density lipoprotein physico-chemical properties. , 2010, Chemistry and physics of lipids.

[7]  H. Jakubowski,et al.  Modulation of paraoxonase 1 and protein N-homocysteinylation by leptin and the synthetic liver X receptor agonist T0901317 in the rat. , 2009, The Journal of endocrinology.

[8]  J. Bełtowski,et al.  Adipose tussue and homocysteine metabolism , 2009 .

[9]  Youguang Huang,et al.  Hyperhomocysteinemia stimulates hepatic glucose output and PEPCK expression. , 2009, Acta biochimica et biophysica Sinica.

[10]  Y. Siow,et al.  Induction of hepatic cyclooxygenase-2 by hyperhomocysteinemia via nuclear factor-kappaB activation. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[11]  J. Delabar,et al.  Effects of red wine polyphenolic compounds on paraoxonase-1 and lectin-like oxidized low-density lipoprotein receptor-1 in hyperhomocysteinemic mice. , 2009, The Journal of nutritional biochemistry.

[12]  R. Obeid,et al.  Homocysteine and lipids: S‐Adenosyl methionine as a key intermediate , 2009, FEBS letters.

[13]  S. Doǧru-Abbasoǧlu,et al.  Oxidative and nitrosative stress and apoptosis in the liver of rats fed on high methionine diet: protective effect of taurine. , 2009, Nutrition.

[14]  R. Muniyappa,et al.  Comparison between surrogate indexes of insulin sensitivity/resistance and hyperinsulinemic euglycemic clamp estimates in rats. , 2008, American journal of physiology. Endocrinology and metabolism.

[15]  J. Delabar,et al.  Resveratrol supplementation worsen the dysregulation of genes involved in hepatic lipid homeostasis observed in hyperhomocysteinemic mice. , 2009, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[16]  P. Aukrust,et al.  The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects. , 2008, The Journal of nutrition.

[17]  Yuan-Yuan Shi,et al.  Hyperhomocysteinemia induced by methionine supplementation does not independently cause atherosclerosis in C57BL/6J mice , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Xian Wang,et al.  Homocysteine Upregulates Resistin Production From Adipocytes In Vivo and In Vitro , 2008, Diabetes.

[19]  C. McClain,et al.  Inhibition of adiponectin production by homocysteine: A potential mechanism for alcoholic liver disease , 2008, Hepatology.

[20]  A. Camproux,et al.  Homocysteine threshold value based on cystathionine beta synthase and paraoxonase 1 activities in mice , 2007, European journal of clinical investigation.

[21]  R. Rozen,et al.  Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. , 2007, Atherosclerosis.

[22]  J. Golbahar,et al.  Hyperhomocysteinemia induces insulin resistance in male Sprague-Dawley rats. , 2007, Diabetes research and clinical practice.

[23]  J. Delabar,et al.  Effects of catechin on homocysteine metabolism in hyperhomocysteinemic mice. , 2007, Biochemical and biophysical research communications.

[24]  K. Eder,et al.  Homocysteine Thiolactone-Induced Hyperhomocysteinemia Does Not Alter Concentrations of Cholesterol and SREBP-2 Target Gene mRNAs in Rats , 2007, Experimental biology and medicine.

[25]  R. Hui,et al.  Hyperhomocysteinemia Decreases Circulating High-Density Lipoprotein by Inhibiting Apolipoprotein A-I Protein Synthesis and Enhancing HDL Cholesterol Clearance , 2006, Circulation research.

[26]  O. Christophe,et al.  Paraoxonase-1 expression is up-regulated in Down syndrome fetal liver. , 2006, Biochemical and biophysical research communications.

[27]  F. Trivin,et al.  Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. , 2006, Clinical biochemistry.

[28]  C. Woo,et al.  Hyperhomocysteinemia induces liver injury in rat: Protective effect of folic acid supplementation. , 2006, Biochimica et biophysica acta.

[29]  J. Joven,et al.  Influence of PON1 polymorphisms on the association between serum paraoxonase 1 and homocysteinemia in a general population. , 2006, Clinical chemistry.

[30]  R. Rozen,et al.  Elevated Homocysteine Reduces Apolipoprotein A-I Expression in Hyperhomocysteinemic Mice and in Males With Coronary Artery Disease , 2006, Circulation research.

[31]  R. Castro,et al.  Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: An overview , 2006, Journal of Inherited Metabolic Disease.

[32]  K. Eder,et al.  Methionine-Induced Elevation of Plasma Homocysteine Concentration Is Associated with an Increase of Plasma Cholesterol in Adult Rats , 2006, Annals of Nutrition and Metabolism.

[33]  G. Karikas,et al.  Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece , 2006, Clinical chemistry and laboratory medicine.

[34]  G. Minuk,et al.  Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors. , 2005, American journal of physiology. Endocrinology and metabolism.

[35]  V. Sánchez-Margalet,et al.  Homocysteine thiolactone inhibits insulin-stimulated DNA and protein synthesis: possible role of mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3) and p70 S6K phosphorylation. , 2005, Journal of molecular endocrinology.

[36]  R. Barouki,et al.  Inverse correlation between phenylacetate hydrolase activity of the serum PON1 protein and homocysteinemia in humans , 2005, Thrombosis and Haemostasis.

[37]  K. Namekata,et al.  Abnormal Lipid Metabolism in Cystathionine β-Synthase-deficient Mice, an Animal Model for Hyperhomocysteinemia* , 2004, Journal of Biological Chemistry.

[38]  R. Barouki,et al.  Mouse liver paraoxonase-1 gene expression is downregulated in hyperhomocysteinemia , 2004, Thrombosis and Haemostasis.

[39]  H. Blom,et al.  Endothelium-Derived Hyperpolarizing Factor–Mediated Renal Vasodilatory Response Is Impaired During Acute and Chronic Hyperhomocysteinemia , 2004, Circulation.

[40]  K. Robert,et al.  Altered Gene Expression in Liver from a Murine Model of Hyperhomocysteinemia* , 2003, Journal of Biological Chemistry.

[41]  G. Ferretti,et al.  Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. , 2003, Metabolism: clinical and experimental.

[42]  M. Kurabayashi,et al.  Diet-induced mild hyperhomocysteinemia and increased salt intake diminish vascular endothelial function in a synergistic manner , 2002, Journal of hypertension.

[43]  Yuan-Yuan Shi,et al.  Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. , 2001, The Journal of clinical investigation.

[44]  V. Laudet,et al.  The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates* , 1998, The Journal of Biological Chemistry.